Myriad Genetics Expands Minimal Residual Disease Testing for Three Cancer Types
The whole-genome sequencing assay is now available for breast, colorectal, and renal cancers following new clinical study results.
The whole-genome sequencing assay is now available for breast, colorectal, and renal cancers following new clinical study results.
The companion diagnostic evaluates mismatch repair deficiency, a predictive biomarker used to identify patients who may respond to PD-1-targeted therapies.
The updated test includes additional DPYD variants recommended by the Association for Molecular Pathology to help identify patients who may be at risk for severe chemotherapy side effects.
The diagnostic test identifies specific genetic mutations to help select patients for a targeted therapy combination.
Read MoreThe test uses a new approach to identify signs of cancer recurrence with faster result times for healthcare providers and patients.
Read MoreClinical results show high sensitivity for colorectal cancer relapse and ultra-low detection limits for lung cancer.
Read MoreThe tissue- and blood-based tests identify patients with specific gene mutations who may benefit from a combination therapy.
Read MoreResults from the PATHFINDER 2 trial show the Galleri test identifies 6.5 times more cancers when used with standard screenings.
Read MoreThe authorization from the New York State Department of Health makes the screening test available in all 50 states.
Read MoreThe multicenter study will evaluate proactive outreach to at-risk relatives and the impact of multigene panel testing on patient care.
Read MoreThe study identifies HAVCR1 as a tool for earlier detection and treatment monitoring for primary central nervous system lymphoma.
Read MoreThe panel integrates biomarker testing and digital tools to support fibrosis risk assessment and liver cancer surveillance.
Read MoreThe funding will support commercial expansion of the company’s blood-based diagnostic tests and the appointment of a new president and chief operating officer.
Read MoreThe new recommendations add blood-based testing and multi-target stool testing as options for average-risk adults starting at age 45.
Read MoreThe $750 million deal aims to integrate AI-powered technology and image management systems into pathology laboratory workflows.
Read MoreResearch presented at ESTRO 2026 suggests circulating tumor DNA can identify which patients will benefit from combined radiation and drug therapy.
Read MoreThe tissue-based test identifies patients with MET exon 14 skipping alterations eligible for treatment with tepotinib.
Read MoreTempus has launched the ArteraAI Prostate Test, a CLIA-certified, CAP-accredited AI tool for metastatic hormone-sensitive prostate cancer, offering personalized risk estimates and designed to support treatment decisions, according to the company.
Read More